About
Soterix Medical® Inc. (SMI) is a medical technology company founded in 2008, specializing in innovative treatments for neuropsychiatric and neurological disorders. The company is a leader in clinical trials for non-invasive neuromodulation, collaborating with over 1,050 medical centers worldwide, including locations in the US, Europe, Canada, Brazil, and Australia. SMI focuses on advancing non-invasive brain stimulation technologies, particularly transcranial Direct Current Stimulation (tDCS) and High-Definition tDCS (HD-tDCS). Their flagship product, the 1x1 tDCS platform, is recognized for its precision and reliability in clinical trials. The company also offers a range of accessories and software tools to enhance the usability of their devices. In addition to device manufacturing, Soterix Medical provides services in image analysis and computational modeling, supporting various applications in research and clinical settings. Their global reach is bolstered by partnerships with academic institutions, hospitals, and research organizations dedicated to advancing neuromodulation therapies.
Technologies
Keywords
Company Information
-
Employees 36
-
Founded 2008
-
Annual Revenue $5000000
-
Total Funding $2500000
Location
237 W 35th St, New York, New York, United States, 10001